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1. Introduction 2. Materials and methods 
Tubulin possesses two distinct binding sites for 
vinblastine; one of high affinity (Ka = 6.2 X 106M” ) 
occupancy of which prevents polymerization of tubulin 
and a second, lower affinity site (K, = 8 X 104M”) 
occupancy of which correlates with the aggregating 
effects of the alkaloid on tubulin [l]. The recent 
report [2] that maytansine, a new antitumor agent of 
plant origin [3,4] , was a potent competitive inhibitor 
of 3H vincristine binding in rat brain homogenates, led 
us to investigate which of the two vinblastine-binding 
sites would be involved in this effect. The formulae of 
these two compounds are shown below (fig.1). 
For polymerization experiments, tubulin was 
purified from rat brain extracts by three cycles of 
polymerization and depolymerization, according to 
the method of Shelanski et al. [5]. The kinetics of 
tubule assembly have been studied by turbidimetric 
measurements at 400 nm as described by Gaskin et al. 
[6] in a temperature-controlled chamber of a Cary 
spectrophotometer (model 14) at 37’C. The poly- 
merization buffer contained 0.1 M 2-(N-morpholino- 
ethane-sulfonic acid) (Mes) buffer, pH 6.4, 1 mM 
ethylene glycol-bis@amino-ethyl ether)-N,N’- 
tetraacetic acid (EGTA), 1 mM GTP and 0.5 n&i 
MgClz. Colchicine binding was determined by a modi- 
fication of the DEAE-filter paper method [7]. 
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2.1. Vinblastine binding assay 
The DEAE-filter paper disc assay for colchicine 
had to be modified to make it suitable for vinblastine- 
Fig.1. VINBLASTINE MAYTANSINE 
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binding. Two DE-81 paper discs (Whatman) were 
washed with cold PMG buffer (10 mM sodium phos- 
phate, pH 6.8, 10 mM MgClz, 0.1 mM GTP solution) 
4’C), by mild suction, taking care not to dry the 
paper. The sample (100 /.d) was applied and was 
absorbed on to filters over a period of l-2 min. The 
filters were then rinsed four times with 4 ml of cold 
(4°C) PMG buffer by mild suction. The radioactivity 
of the filter papers was determined in 10 ml of 
Hydromix (Yorktown). In all cases, controls were 
run in the absence of tubulin and this blank value 
was subtracted from the quantity of vinblastine 
bound in the presence of tubulin. Binding results of 
duplicate xperiments agreed to within 10%. The 
concentration of protein was determined by the 
method of Lowry et al. [8] with crystalline bovine 
albumin as a standard. 
GTP (Grade II-S) was obtained from Sigma. 
Tritiated colchicine (ring C, [3H]methoxy) a product 
of New England Nuclear Corp., had a specific activity 
of 18.45 Ci/mmol. [3H]Vinblastine was prepared as 
described and had a specific activity about 19 Ci/mmol 
and about 95% radiochemical purity [9] or was 
purchased from Amersham-Searle (13.5 Ci/mmol). 
Vinblastine was a gift of Eli Lilly Laboratories. 
Maytansine was generously supplied by Dr David G. 
Johns of the National Cancer Institute. 
3. Results 
Since vinblastine-binding can be indirectly measur- 
ed by its effect on the state of aggregation of tubulin 
[ 11, we compared the effects of maytansine and 
vinblastine on the polymerization of rat brain tubulin. 
As shown in fig.2, both drugs prevented polymeriza- 
tion in the micromolar range. The concentration for 
SO% inhibition was 0.35 X 10s6 M for maytansine and 
0.20 X 10m6 M for vlnblastine. While the relative poten- 
cies were more different than expected [2] , the effects 
were parallel throughout the concentration range. 
In contrast o the similarity between the drug 
effects at low concentrations, when the concentra- 
tion range for low affinity vinblastine-binding [I] 
was investigated, marked differences between these 
two drugs were observed (fig.3). As shown previously 
[ 1] , vinblastine caused tub&n aggregation with a 
half-maximal concentration of 2 X 10q5 M (followed 
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Fig.2. Effects of antimitotic drugs on tubulin polymerization. 
Aliquots of tubulin (2.1 mglml) in polymerization buffer 
were mixed with different concentrations of maytansine and 
vinblastine immediately before incubation at 37°C. The 
polymerization was monitored by optical density at 400 nm 
in a temperature-controlled recording spectrophotometer. 
Data are expressed as the percent of the maximal plateau 
level reached without drug. 
by precipitation at concentrations > 1 X 1 OS3 M). 
In marked contrast, maytansine was totally unable 
to promote tubulin polymerization up to concentra- 
tions > 1 X low3 M. Nevertheless, preincubation of 
tubulin preparations with 3 X 1 O4 M maytansine 
prevented the subsequent effect of vinblastine at this 
site and suggested that vinblastine could bind to the 
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Fig.3. Effects of antimitotic drugs on tubulin aggregation. 
Tubulin (0.75 mg/ml) in polymerization buffer was titrated 
with increasing concentrations of drugs as follows: curve 1, 
vinblastine, curve 2, maytansine and curve 3, first preincubat- 
ed with 3 X 1 O-’ M maytansine and then titrated with 
vinblastine. After each addition of drug, the solution was 
incubated for 15 min at 37”C, after which the optical density 
was measured at 400 nm. 
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Fig.4.A. Left panel. Dixon plot demonstrating the effect of maytansine on the vinblastine-binding reaction. The concentration 
of maytansine present is plotted against the reciprocal of the moles of vinblastine bound per mole of tubulin, B, at several concen- 
tsations of vinblastine: (A) 1 X 10"6,(e) 0.75 X 10 -6, (o) 0.5 X 10 -s. The reaction mixtures in PMG buffer, pH 6.8, were incubat- 
ed at 37°C for 30 rain and binding was assayed by the DEAE-filter disc method. Fig.4.B. Right panel. Inhibition of vinblastine- 
binding to the low affinity site of tubulin by maytansine. The aged tubulin used in this experiment was devoid of vinblastine- 
binding to the high affinity site of tubulin. The reaction mixtures contained 5 × 10 "~ M tubulin and 2.5 X 10 -s M vinblastine 
in PMG buffer and were incubated at 37°C for 30 rain. 
low affinity site but was not able to promote 
aggregation. 
Binding of maytansine to the two vinblastine- 
binding sites was measured irectly as the blocking 
of [3H]vinblastine by the macrolide. As shown by the 
Dixon plot in rigA, the high affinity site is blocked 
competitively by maytansine yielding an apparent 
K i "~ 0.5 X 10 -4 M. Similarly, the low affinity site 
could be blocked competitively by maytansine. Since, 
however, displacement from this second site can be 
confused by displacement from the high affinity site, 
we chose another method to investigate the low 
affinity vinblastine site. 
Tubulin can be aged at 4°C until the high affinity 
vinblastine-binding site is entirely lost with little 
damage in binding to the low affinity site [ 1 ]. Such 
tubulin preparations were used in fig.4B. The results 
again show that maytansine is a competitive inhibitor 
of [SH]vinblastine-binding (apparent K i = 4.4 X 10 -s 
M). Clearly, therefore, despite rather different 
properties of the two vinblastine-binding sites, both 
bind maytansine competitively. 
Vinblastine is well known for its ability to protect 
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Fig.5. Effect of preincubation at 3TC of rat brain tubulin 
on colchicine binding. Tubufin was incubated at 37°C for 
the indicated period. The conditions of preincubation arc: 
curve 1 tubulin in PMG buffer (o). Curve 2, tubulin in PMG 
buffer containing 3X 10 -4 M maytansine (A). Curve 3, 
tubufin in PMG buffer containing 3X 10 -4 M vinblastine 
(e). Samples were preincubated at 37°C and the colchicine- 
binding activity was measured for 1 h at 37°C. 
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the colchicine binding site of tubulin [lo] although 
the nature of this protective ffect is not yet under- 
stood. Maytansine (0.3 mM) was not, however, able 
to elicit a similar stabilization of the colchicine- 
binding site (fig.5). 
Maytansine isa potent antileukemic ansa macrolide 
isolated from Maytemus buchananii and Maytemus 
set-rata [3,4]. Preliminary studies had shown an 
increased mitotic index and a DNA content charac- 
teristic of the Gz t M phases of the cell cycle [ 11,121. 
Furthermore, low concentrations of maytansine 
completely inhibited cleavage of sea urchin eggs [ 131. 
Since there was cross resistance between vincristine 
and maytansine in certain cell lines [ 1 I] , the effect 
of the macrolide on vincristine-binding to tubulin 
was investigated [2] . In the present study we confirm 
the conclusion that maytansine isa competitive 
inhibitor of binding for the vinca alkaloids. This 
effect is exerted at both the high and low affinity 
binding sites and occurs with a potency (Ki) in the 
range of vinblastine [ 11. Interaction with the high 
affinity site is accompanied by depolymerization of
microtubules, as also shown by Remillard et al. [13] . 
However, interaction at low affinity site, while easily 
measured by binding studies, is not accompanied by 
aggregation a d prevents the aggregating effect of 
vinblastine. Moreover, unlike vinblastine, maytansine 
does not protect he independent colchicine-binding 
site. Whether this implies that the aggregating effect 
of the vinca alkaloids is the result of their dimeric 
nature remains to be determined. 
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